Clinical Diagnostics
New at Lucron!
ViroGates has developed a unique prognostic biomarker - suPARnostic®, measuring the soluble blood protein suPAR, present in everybody. Independent of the respective condition, an elevated suPAR level is a master alarm for a patient's risk status. In clinical practice suPARnostic® can be used for patient triaging in critical care as well as monitoring of treatment efficacy and success. suPARnostic®'s amazing prognostic value has already been exemplified in various infectious conditions, these include sepsis/SIRS, tuberculosis and HIV.
ViroGates first commercial suPARnostic® product is an ELISA-based test that has been launched in certain European, African and Asian countries. Further products are being developed - a lateral flow rapid test, as well as line extensions to the ELISA test.
Please contact our Lucron office for more information.
|
||||
|
||||
